April 10, 2021
Shasqi will present preclinical data and the Phase 1 clinical trial design for its lead clinical candidate, SQ3370, at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
February 10, 2021
Shasqi announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
January 27, 2021
Shasqi announced today the publication of two preclinical studies highlighting the potential of the company’s click chemistry-based approach to the development of treatments for a range of solid cancers.
January 07, 2021
Shasqi, a clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies, announced today that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday January 13th at 2:00pm Eastern Time.
November 20, 2020
Shasqi presents two posters at The Connective Tissue Oncology Society (CTOS) 25th Anniversary Annual Meeting showcasing their lead candidate SQ3370.
November 12, 2020
Shasqi presents two posters on their lead candidate, SQ3370, at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting.
October 14, 2020
First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies. Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies. SAN FRANCISCO, CA. – October 14, 2020 – Shasqi announced today the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370.
October 08, 2020
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today that the Company has appointed Wayne Saville, M.D., as Chief Medical Officer, and Juan Jaen, Ph.D., President & Co-founder of Arcus Biosciences, as a member of the Shasqi board of directors.
June 22, 2020
Shasqi, a leader in chemistry based locally-activated cancer drugs, presented data showing that the company’s lead candidate SQ3370 produced robust anti-tumor responses both at the target site and at distal lesions in a preclinical cancer model. The study, titled “SQ3370, a Local Activation Therapy of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation,” was presented in a poster with audio at the American Association for Cancer Research Virtual Annual Meeting II.
October 31, 2019
Shasqi, Inc., a privately held company focused on improving the localized delivery of cancer drugs to tumors, today announced the completion of a $10 million Series A financing. The proceeds of the financing are being used to complete GMP manufacturing for the company’s lead drug candidate and to support a Phase 1 human trial, expected to commence in Q2 2020.
July 20, 2016
Scientists at Shasqi, Inc. and SUNY University at Albany have published research demonstrating a way to target drugs to specific areas of the body, enabling greater efficacy and fewer side-effects. The method, called local drug activation, uses activating agents in an injected polymer gel to concentrate and activate prodrug versions of a drug, such as a chemotherapeutic, directly at a desired location, limiting the drug's action to that specific site. The researchers recently published their findings online in ACS Central Science, the open-access flagship journal of the American Chemical Society.